Sanofi turns to China for R&D partnerships

The R&D wing at Sanofi-Aventis is turning to China to find new ways to fight cancer and rheumatoid arthritis. The French pharma giant wants to forge a half dozen research partnerships with scientists in state-funded labs and Chinese universities. Analysts note that while China has become a key player for low cost- -and sometimes high risk--drug manufacturing, Chinese officials have been investing huge sums to build up its drug research operations. China intends to become a leader in drug research, and the world's drug developers are playing close attention to the opportunities that trend will offer them.

"I think the amount of people with a master's in biology in China is now bigger than the number of people with a master's in biology in the U.S.," Marc Cluzel (photo), head of Sanofi's R&D, tells the Wall Street Journal. "The number of people with a Ph.D. in biology in the U.S. is still higher than in China, but it's getting closer and closer. And they are doing some good fundamental science."

- read the report in the Wall Street Journal

Related Articles:
Sanofi makes moves in China. Report
Sanofi signs stem cell pact in China. Report
Sanofi to build vaccine plant in China. Report
China pushes drug development as R&D soars. Report

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.